Amgen updates agreement with DaVita for dialysis treatment
Thousand Oaks biotech company Amgen entered into a six-year supply agreement with DaVita for dialysis treatments, the company announced on Jan. 9.
Under the terms of the new agreement, Amgen will supply DaVita with Epogen and Aranesp for agents to stimulate red blood cells in dialysis treatment in the United States and Puerto Rico. The new agreement, which offers discount pricing and rebates, will replace the Nov. 15, 2011 agreement that would have expired on Dec. 31, 2018.
Amgen shares went up 1.3 percent to $158.84 on Jan. 9.
• Contact Alex Kacik at [email protected].
